Literature DB >> 8245670

Pattern of recurrence in rectal carcinoma: implications for the design of (future) studies on adjuvant therapy.

J P Barras1, R Bachmann, P Aeberhard.   

Abstract

255 patients who underwent potentially curative surgical treatment for rectal carcinoma at the Cantonal Hospital Aarau from 1981 to 1989 have been followed up and the results analysed for overall survival and the timing and occurrence of local and distant recurrence in relation to the initial tumor stage. The patients had received standard surgical treatment for rectal carcinoma with the exception of 28 patients who had been randomized to the treatment arm of SAKK protocol 40/81 and were given perioperative adjuvant portal chemotherapy. 10 patients with large fixed tumors had preoperative radiation therapy. In UICC stage I most patients were cured by surgery alone, local recurrence as rare, and distant metastases appear in about 10% of pT2. cases. In stage II about one fifth of the patients developed a recurrence with one third of them having only local recurrence, and two thirds having either combined local and distant recurrence or distant recurrence alone. The small subgroup of pT4 pN0 had a very poor prognosis with early occurrence of distant metastases. In stage III the actuarial five-year survival was 25%, 60% of stage III cases had pN1 nodal disease. No patient with pN2-3 disease was alive after five years follow-up. The overall risk of distant metastases in stage III was 64%. Local recurrence rate was highly dependent on the pT-stage.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8245670     DOI: 10.1007/bf00341187

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  12 in total

Review 1.  NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer.

Authors: 
Journal:  JAMA       Date:  1990-09-19       Impact factor: 56.272

2.  Randomized multicenter trial of adjuvant intraportal chemotherapy for colorectal cancer (SAKK 40/81). An interim report.

Authors:  U Metzger; U Laffer; P Aeberhard; M Arigoni; S Arma; J Barras; R Egeli; S Martinoli; W Mueller; W Schweizer
Journal:  Acta Chir Scand       Date:  1990 Jun-Jul

3.  Local recurrence of adenocarcinoma of the rectosigmoid. Is postoperative adjuvant radiotherapy justified?

Authors:  R M Auld; S B Chapman; G G Kuster; P Foroozan
Journal:  Dis Colon Rectum       Date:  1986-05       Impact factor: 4.585

4.  A universal staging system for cancer of the colon and rectum. Let there be light.

Authors:  R V Hutter; L H Sobin
Journal:  Arch Pathol Lab Med       Date:  1986-05       Impact factor: 5.534

5.  The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma.

Authors:  G J Offerhaus; E P De Feyter; C J Cornelisse; K W Tersmette; J Floyd; S E Kern; B Vogelstein; S R Hamilton
Journal:  Gastroenterology       Date:  1992-05       Impact factor: 22.682

6.  Carcinoma of the rectum: a 10-year experience.

Authors:  A R Dixon; W A Maxwell; J T Holmes
Journal:  Br J Surg       Date:  1991-03       Impact factor: 6.939

7.  Recurrence rates after curative surgery for rectal carcinoma, with special reference to their accuracy.

Authors:  U Carlsson; A Lasson; G Ekelund
Journal:  Dis Colon Rectum       Date:  1987-06       Impact factor: 4.585

Review 8.  Radiation therapy in the management of rectal cancer.

Authors:  K L Griem
Journal:  Hematol Oncol Clin North Am       Date:  1989-03       Impact factor: 3.722

9.  Effective surgical adjuvant therapy for high-risk rectal carcinoma.

Authors:  J E Krook; C G Moertel; L L Gunderson; H S Wieand; R T Collins; R W Beart; T P Kubista; M A Poon; W C Meyers; J A Mailliard
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

10.  [DNA content and c-erbB-2 oncoprotein expression in hepatic metastases from colorectal carcinoma--in relation to clinicopathologic findings and prognosis].

Authors:  K Omori
Journal:  Nihon Geka Gakkai Zasshi       Date:  1991-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.